Issues Related to the Frequency of Exploratory Analyses by Evidence Review Groups in the NICE Single Technology Appraisal Process [0.03%]
证据回顾组在英国NICE单一技术评估过程中探索性分析的频次问题探讨
Eva Kaltenthaler,Christopher Carroll,Daniel Hill-McManus et al.
Eva Kaltenthaler et al.
Background: Evidence Review Groups (ERGs) critically appraise company submissions as part of the National Institute for Health and Care Excellence (NICE) Single Technology Appraisal (STA) process. As part of their critiqu...
Economic Impact of Mirabegron Versus Antimuscarinics for the Treatment of Overactive Bladder in the UK [0.03%]
英国尿失禁患者采用mirabegron治疗相比抗胆碱药物的经济影响研究
Jameel Nazir,Malin Berling,Charles McCrea et al.
Jameel Nazir et al.
Purpose: Our objective was to estimate the economic outcomes of using mirabegron versus antimuscarinics in the treatment of patients with overactive bladder (OAB) from a societal perspective in the UK. ...
Authors' Reply to Holko: "Forecasting Pharmaceutical Prices for Economic Evaluations When There Is No Market: A Review" [0.03%]
作者回复霍尔科关于“当没有市场时，药品经济评估中的药品价格预测回顾”的评论
Ilke Akpinar,Philip Jacobs,Dat T Tran
Ilke Akpinar
Population Screening for Hereditary Haemochromatosis in Australia: Construction and Validation of a State-Transition Cost-Effectiveness Model [0.03%]
澳大利亚遗传性血色病筛查的州转移成本效益模型的构建及验证
Barbara de Graaff,Lei Si,Amanda L Neil et al.
Barbara de Graaff et al.
Introduction: HFE-associated haemochromatosis, the most common monogenic disorder amongst populations of northern European ancestry, is characterised by iron overload. Excess iron is stored in parenchymal tissues, leading...
Forecasting Pharmaceutical Prices for Economic Evaluations When There Is No Market: A Review [0.03%]
无市场价格情况下的卫生技术评估药品价格预测方法学研究
Ilke Akpinar,Philip Jacobs,Tien Dat Tran
Ilke Akpinar
Background: Economic evaluation helps policy makers and healthcare payers make decisions on drug listing, coverage, and reimbursement. When economic evaluations are conducted before a product launch, the prices of the pha...
Communal Sharing and the Provision of Low-Volume High-Cost Health Services: Results of a Survey [0.03%]
互助型卫生筹资与高成本低用量的卫生服务：一项调查结果
Jeff Richardson,Angelo Iezzi,Gang Chen et al.
Jeff Richardson et al.
Introduction: This paper suggests and tests a reason why the public might support the funding of services for rare diseases (SRDs) when the services are effective but not cost effective, i.e. when more health could be pro...
A Single-Center Cost Analysis of Treating Primary and Metastatic Brain Cancers with Either Brain Laser Interstitial Thermal Therapy (LITT) or Craniotomy [0.03%]
单中心治疗原发性和转移性脑瘤的脑激光间质热疗与开颅手术成本分析
Eric C Leuthardt,Jeff Voigt,Albert H Kim et al.
Eric C Leuthardt et al.
Background: Brain laser interstitial thermal therapy (LITT) under magnetic resonance imaging (MRI) guidance has recently gained US clinical approval for the ablation of soft, neurological tissue. LITT is a minimally invas...
Economic Evaluation of Fulvestrant 500 mg Compared to Generic Aromatase Inhibitors in Patients with Advanced Breast Cancer in Sweden [0.03%]
瑞典晚期乳腺癌患者使用 fulvestrant 500 毫克与仿制芳香化酶抑制剂的经济性评估
Ugne Sabale,Mattias Ekman,Daniel Thunström et al.
Ugne Sabale et al.
Objectives: In Sweden, breast cancer (BC) represents 30% of newly diagnosed cancers and is the most common cancer in women. For hormone-dependent BC, endocrine therapies varying in efficacy and price are available. The ai...
Development of a Procedure for the Government Provision of Bone-Anchored Prosthesis Using Osseointegration in Australia [0.03%]
在澳大利亚开发政府提供以骨整合为基础的骨锚式助听装置的实施程序
Laurent Frossard,Gregory Merlo,Tanya Quincey et al.
Laurent Frossard et al.
Background: Governmental organizations are facing challenges in adjusting procedures providing equitable assistance to consumers with amputation choosing newly available osseointegrated fixations for bone-anchored prosthe...